AIMS: Chronic kidney disease (CKD) challenges diabetes management and is associated with increased cardiovascular morbidity and mortality. We examined whether clinical outcomes with insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (IDeg-100) are affected by renal function in a prespecified subgroup analysis from the BRIGHT trial. MATERIALS AND METHODS: BRIGHT (NCT02738151) was a multicentre, open-label, randomized, active-controlled, two-arm, parallel-group, 24-week study in insulin-naïve uncontrolled type 2 diabetes (T2D). Participants were randomized 1:1 to evening Gla-300 (n = 466) or IDeg-100 (n = 463) and stratified based on baseline estimated glomerular filtration rate (eGFR) for this analysis. RESULTS: Heterogeneity of treatment effect across renal function subgroups was observed (P = .02), reflecting a greater mean glycated haemoglobin (HbA1c) reduction from baseline to week 24 with Gla-300 versus IDeg-100 in the eGFR <60 mL/min/1.73 m2 subgroup (least squares mean difference: -0.43% [95% confidence interval: -0.74% to -0.12%]), while there were no differences in hypoglycaemia incidence or rates over 24 weeks in that subgroup. HbA1c reductions were similar between treatments in the other eGFR subgroups. However, heterogeneity was observed for annualized rates of anytime (24 hours) or nocturnal (00:00-05:59 hours) confirmed hypoglycaemia (≤70 mg/dL [≤3.9 mmol/L]) over 24 weeks showing less hypoglycaemia with Gla-300 versus IDeg-100 in the ≥90 mL/min/1.73 m2 . CONCLUSIONS: Kidney function seems to affect the glucose-lowering effects of Gla-300 versus IDeg-100 in insulin-naïve T2D. Greater HbA1c reductions with Gla-300 without increase in hypoglycaemia risk, were observed in patients with eGFR <60 mL/min/1.73 m2 .

Dallas Diabetes Research Center at Medical City Dallas Texas

Department of Cardiology University Hospital RWTH Aachen Aachen Germany

Department of Diabetes and Endocrinology Guy's and St Thomas' NHS Trust London UK

Department of Medicine University of Toronto Toronto Ontario Canada

Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Ividata Levallois Perret France

Sanofi Paris France

Section of Endocrinology and Metabolism Department of Medicine Perugia University Medical School Perugia Italy

Zobrazit více v PubMed

Papademetriou V, Lovato L, Doumas M, et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015;87(3):649‐659. PubMed

Alsahli M, Gerich JE. Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc. 2014;89(11):1564‐1571. PubMed

Rabkin R. Diabetic nephropathy. Clin Cornerstone. 2003;5(2):1‐11. PubMed

MacIsaac RJ, Jerums G, Ekinci EI. Effects of glycaemic management on diabetic kidney disease. World J Diabetes. 2017;8(5):172‐186. PubMed PMC

Becker RH, Nowotny I, Teichert L, Bergmann K, Kapitza C. Low within‐ and between‐day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17(3):261‐267. PubMed PMC

Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859‐864. PubMed

Porcellati F, Lucidi P, Candeloro P, et al. Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes. Diabetes Care. 2019;42(1):85‐92. PubMed

Lucidi P, Porcellati F, Cioli P, et al. Greater suppression of glucagon, lipolysis, and ketogenesis with insulin glargine U300 as compared with glargin U100 in type 1 diabetes mellitus. Diabetes Technol Ther. 2020;22(1):57–61. PubMed

Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6‐month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755‐2762. PubMed

Yki‐Jarvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension. Diabetes Obes Metab. 2015;17(12):1142‐1149. PubMed PMC

Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naive people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386‐394. PubMed PMC

Roussel R, Ritzel R, Boelle‐Le Corfec E, Balkau B, Rosenstock J. Clinical perspectives from the BEGIN and EDITION programmes: trial‐level meta‐analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM. Diabetes Metab. 2018;44(5):402‐409. PubMed

Kiss I, Arold G, Roepstorff C, Bøttcher S, Kilm S, Haahr H. Insulin degludec: pharmachokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53:175‐183. PubMed PMC

Nordisk Novo. TRESIBA® (insulin degludec) Prescribing Information. U.S Food and Drug Administration. www.accessdata.fda.gov/drugsatfda_docs/label/2019/203314s015s016lbl.pdf. 2019. Accessed November 29, 2019.

Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 units/mL versus insulin Degludec 100 units/mL in insulin‐naive type 2 diabetes: the randomized head‐to‐head BRIGHT trial. Diabetes Care. 2018;41(10):2147‐2154. PubMed

Landgraf W, Owens DR, Frier BM, Zhang M, Bolli GB. Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL. Diabetes Obes Metab. 2020;22(3):315–323. PubMed

Kawaguchi Y, Sawa J, Hamai C, Kumeda Y. Differential effect of hypoalbuminemia on hypoglycemia on type 2 diabetes patients treated with insulin glargine 300 U/mL and insulin degludec. Diabetes Ther. 2019;10(4):1535‐1541. PubMed PMC

Pieber TR, Bardtrum L, Isendahl J, Wagner L, Nishimura R. Commentary to "Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec" by Kawaguchi et al. Diabetes Therapy 2019″. Diabetes Ther. 2020;11(2):561–567. PubMed PMC

Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel